Oric Pharmaceuticals Inc at AACR-NCI-EORTC Virtual International Conference Transcript
Good day, and thank you for standing by, and welcome to the ORIC Pharmaceuticals Business Update Conference Call. (Operator Instructions)
I would now like to hand the conference over to your speaker today, Dominic Piscitelli, Chief Financial Officer. Please go ahead.
Good morning, and welcome to the ORIC Pharmaceuticals Business Update, AACR-NCI-EORTC Conference Call. This morning, we issued a press release highlighting initial clinical and translational data from our ongoing Phase Ib trial of ORIC-101 in combination with enzalutamide in patients with metastatic prostate cancer as well as preclinical data on ORIC-114 in HER2-positive breast cancer.
You may find the press release posted on the Investor page of oricpharma.com. We have per-recorded our prepared remarks, after which we will host a live Q&A session. So please bear with us if we have any technical difficulties.
Before we begin, starting on Slide 2. During this conference call, we will be making forward-looking
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |